CASI PHARMACEUTICALS ANNOUNCES RENEWAL OF EXCLUSIVE DISTRIBUTION AGREEMENT FOR EVOMELA® IN CHINA

Rhea-AI Summary

CASI Pharmaceuticals (Nasdaq: CASI) has renewed an exclusive distribution agreement with China Resources Pharmaceutical Commercial Group for EVOMELA® (melphalan) sales in China. This partnership has contributed to rapid revenue growth, reaching $30 million in 2021. The collaboration enhances distribution efficiency, increasing accessibility for healthcare providers and patients. CASI aims to strengthen its market position in China through this agreement and its dedicated hematology oncology sales team.

Positive

• EVOMELA® revenue reached $30 million in 2021.
• The renewal of the distribution agreement ensures continued market presence in China.
• Partnership enhances accessibility of EVOMELA® for physicians and patients.

Negative

• None.

ROCKVILLE, Md. and BEIJING, March 4, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced today, that the Company has entered into a renewal exclusive distribution agreement, whereby under the terms of the agreement, China Resources Pharmaceutical Commercial Group International Trading Co., Ltd. (CRPCGIT), previously called "China Resources Guokang Pharmaceuticals Co., Ltd. (CRGK)",  will continue to be the sole distributor for the sale of EVOMELA^® (melphalan) for Injection in China.

Larry Zhang, CASI's Global President, commented, "EVOMELA^® has shown rapid revenue growth in the past three years and reached $30 million in 2021. In combination with the efforts of all CASI employees, cooperation with CRPCGIT has been tremendously valuable in achieving long-term growth. CRPCGIT provides reliable and efficient distribution services that significantly increase accessibility to EVOMELA^® for physicians and patients. We look forward to our future collaboration."

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the greater China market leveraging the Company's China-based regulatory and commercial competencies and its global drug development expertise. The Company's operations in China are conducted through its wholly-owned subsidiary, CASI Pharmaceuticals (China) Co., Ltd., which is located in Beijing, China. The Company has built a commercial team of more than 100 hematology oncology sales and marketing specialists based in China. More information on CASI is available at www.casipharmaceuticals.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, revenue growth, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and we assume no duty to update forward-looking statements. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Actual results could differ materially from those currently anticipated due to a number of factors.

EVOMELA^® is proprietary to Acrotech Biopharma LLC and its affiliates.

COMPANY CONTACT:	INVESTOR CONTACT:
RuiZhang	Xuan Yang
CASI Pharmaceuticals, Inc	Solebury Trout
240.864.2643	646.378.2975
ir@casipharmaceuticalscom	xyang@soleburytroutcom

View original content to download multimedia:https://www.prnewswire.com/news-releases/casi-pharmaceuticals-announces-renewal-of-exclusive-distribution-agreement-for-evomela-in-china-301495624.html

SOURCE CASI Pharmaceuticals, Inc.

FAQ

What is the latest news for CASI Pharmaceuticals?

CASI Pharmaceuticals renewed its exclusive distribution agreement for EVOMELA® in China.

What revenue did CASI Pharmaceuticals achieve in 2021?

CASI Pharmaceuticals reported $30 million in revenue for EVOMELA® in 2021.

Who is the distributor for EVOMELA® in China?

China Resources Pharmaceutical Commercial Group is the exclusive distributor for EVOMELA® in China.

How has CASI Pharmaceuticals' partnership affected EVOMELA® sales?

The partnership has significantly increased accessibility and contributed to rapid revenue growth.

When was the distribution agreement for EVOMELA® renewed?

The renewal of the distribution agreement was announced on March 4, 2022.